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Abstract Synovial sarcoma (SS) is an aggressive type of
tumor, comprising approximately 10 % of soft tissue sarco-
mas. Over 90 % of SS cases are characterized by the
t(X;18)(p11.2;q11.2) translocation, which results mainly in
the formation of oncogenic SS18-SSX1 or SS18-SSX2
fusions. In a typical SS18-SSX fusion transcript, exon 10
of SS18 is fused to exon 6 of SSX1/2. However, several
variant fusion transcripts have been already described. In the
present study, we examined the fusion transcript type in a
series of 40 primary untreated SS tumor specimens using
reverse transcription polymerase chain reaction and fluo-
rescence in situ hybridization assay. We detected SS18-
SSX1 transcript in 22 (55 %) patients and SS18-SSX2
transcript in 17 (42.5 %) patients, while in one patient,
none of SS18-SSX1/2 fusion transcripts were identified.
Among the cases under study, two tumors carried novel
SS18-SSX1 and SS18-SSX2 variant translocations that
were allegedly created by an alternative splicing, and in
additional case, an unusual translocation variant previous-
ly described by other group was found. Our data suggest
that alternative splicing may play an important role in
novel fusion transcript formation, and additionally we
show that it may be a recurrent event in SS. Furthermore,
we describe the first case of a complex rearrangement
possibly linking SS to REPS2 gene.
Keywords Synovial sarcoma .Molecular markers . Fusion
genes . SS18-SSX fusion genes
Introduction
Synovial sarcoma (SS) accounts for approximately 10 % of
soft tissue sarcomas. SS is an aggressive type of tumor
which may arise in patients at any age but mainly develop
in adolescents and young adults. SS originates principally in
the extremities but may occur at any anatomic site. Metas-
tases, which mainly affect the lungs, occur in approximately
half of patients [1].
Cytogenetically, SS is characterized by the nonrandom
presence of t(X;18)(p11.2;q11.2) [2, 3]. This translocation is
detected in more than 90 % of SS cases and involves the
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SS18 (previously known as SYT) gene on chromosome 18
and one of the SSX genes on the X chromosome [4–6]. In a
typical SS18-SSX fusion transcript, exon 10 of SS18 is fused
to exon 6 of SSX1/2 [7]. Approximately two-thirds of
tumors carry SS18-SSX1 translocation, and the SS18-SSX2
variant is found in one-third of cases [5, 8, 9]. Moreover,
rare cases of SS18-SSX4 chimeric variants in SS have been
described. However, SS18-SSX4 fusions have been charac-
terized by high breakpoint variability, resulting in functional
unpredictability [10–12]. The rare SS cases which lack the
classical SS18-SSX fusion gene may represent tumors with
unusual variant transcripts, which failed to be detected using
conventional approaches [13]. Studies investigating the
prognostic value of the different fusion types provide con-
tradictory results. Several studies reported a more favorable
outcome in patients carrying SS18-SSX2 fusions [5, 11,
14–17], and others failed to find any significant correlation
between fusion type and clinical outcome [9, 18, 19].
In the present study, we examined fusion transcript
type using reverse transcription polymerase chain reac-
tion (RT-PCR) in a series of 40 SS patients. We report
two novel SS18-SSX1 and SS18-SSX2 variant transloca-
tions, and in one patient we detected unusual SS18-




Forty fresh frozen surgical biopsies of primary tumors were
obtained from the University Hospital Leuven, Belgium (n0
39) and the Maria Sklodowska-Curie Memorial Cancer
Centre and Institute of Oncology, Warsaw, Poland (n01).
The specimens originated from 24 males and 16 females
with the mean age at the diagnosis of 38 years (range from 5
to 85 years). All tumors in our cohort were diagnosed as
conventional synovial sarcomas by means of morphology
and routine immunohistochemistry, with 26 tumors being
classified as monophasic and 13 as biphasic. One specimen
presented features of both mono- and biphasic histosub-
types. All specimens were collected with informed consent,
according to the protocol approved by the local ethical
committee. The clinicopathologic data of this series are
shown in Table 1.
Table 2 Primers used for PCR and sequencing
Designation Sequence Direction Position NCBI reference sequence
SS18 5′ AGGATATAGACCAACACAGCC 3′ Forward 1242-1262 NM_001007559.1
SSX1 5′ GGTGCAGTTGTTTCCCATCG 3′ Reverse 493-512 NM_005635.2
SSX2 5′ GGCACAGCTCTTTCCCATCA 3′ Reverse 510-529 NM_175698.1
SSX4 5′ GGCACAGCTGTTTCCCATCA 3′ Reverse 460-479 NM_005636.3
Fig. 1 Detection of novel fusion transcripts by electrophoresis in 2 %
agarose gel stained with ethidium bromide. a Detection of unusual
SS18-SSX1 fusion transcripts. M—1-kb Plus DNA ladder (Invitrogen);
1—344-bp PCR product obtained from primary tumor specimen de-
rived from patient #3; 2—344-bp PCR product obtained from meta-
static tumor specimen derived from patient #3; 3—194-bp PCR
product obtained from primary tumor specimen derived from patient
#29; 4—negative control, no cDNA added; 5—positive control, PCR
product obtained from patient with the SS18-SSX1 fusion confirmed by
sequencing. b Detection of novel SS18-SSX2 fusion transcript. M—1-
kb Plus DNA ladder (Invitrogen); 1—263-bp PCR product obtained
from primary tumor specimen derived from patient #16; 2—negative
control, no cDNA added; 3—positive control, PCR product obtained
from 1273/99 cell line with confirmed SS18-SSX2 fusion transcript
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RNA extraction and reverse transcription
Total RNAwas extracted from fresh frozen tumor specimens
characterized as SS using miRNeasy kit according to the
manufacturer’s protocol (Qiagen). RNA quality was assessed
using BIO-RAD Experion RNA StdSens Analysis system
(BIO-RAD). One microgram of total RNA was reverse tran-
scribed with oligo(dT)12–18 primers and random hexamers
using SuperScript III Reverse Transcriptase (Invitrogen).
Fusion transcript detection by PCR
We performed SS18-SSX1 and SS18-SSX2 detection in all of
examined cases, and additionally SS18-SSX4 detection in
the case negative for SS18-SSX1/2 fusions. PCR was per-
formed with two microliters of cDNA using AmpliTaq Gold
DNA Polymerase (Invitrogen). Amplification was per-
formed at +94 °C for 30 s, +58 °C for 60 s, and +72 °C
for 60 s for 35 cycles, and the final extension was performed
for 10 min. Only the annealing temperature for SS18-SSX4
detection was +57 °C. Primers used for amplification are
listed in Table 2 [20, 21]. cDNA from synovial sarcoma
1273/99 cell line (kindly provided by Professor Fredrik
Mertens, Skone University Hospital, Lund University, Swe-
den) was used as a positive control of SS18-SSX2 amplifi-
cation, and cDNA from patient with known SS18-SSX1,
confirmed by direct sequencing, was used as a positive
control of SS18-SSX1 amplification. Negative controls were
also included in every step of the procedure. PCR products
were analyzed by electrophoresis in 2 % agarose gels
stained with ethidium bromide and photographed.
Sequence analysis
PCR products were purified using QIAquick PCR Purification
Kit (Qiagen). Direct sequencing of both strands of PCR prod-
ucts was performed using BigDye® Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) and analyzed on the
3130xL Genetic Analyzer (Applied Biosystems). Both strands







REPS2 ex6 (136 bp) SSX1 ex5 (50bp) SSX1 ex6 (91bp)5’ 3’
1308 943 1078 5123721242






Fig. 2 Identification of novel
fusion transcript SS18-SSX1
involving REPS2 gene. a
Schematic representation of the
expected PCR product and
novel SS18-SSX1 fusion
transcript. The nucleotide
positions derived from the
original sequences of SS18,
SSX1, and REPS2 mRNA are
indicated in the upper part of
the figure. b Nucleotide
sequence of the 344-bp PCR
product with predicted amino
acid sequence of the chimeric
protein
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Lite 2.01 software (Technelysium Pty Ltd) and BLAST soft-
ware (http://blast.ncbi.nlm.nih.gov/Blast.cgi) were used for the
computer analysis of obtained sequence data.
Fusion type detection by fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) assay was per-
formed in selected cases to confirm the type of SS18-SSX1/2
translocations, according to the protocol described by Sur-
ace and coworkers [22].
Results
We detected SS18-SSX1 transcripts in 55 % (n022) and SS18-
SSX2 transcripts in 42.5 % (n017) of patients. In one tumor,
we did not detect any fusion transcript using RT-PCR;
although FISH was not performed due to insufficient material,
the karyotype of this specimen was available in the hospital
database, revealing a t(X;18). Among analyzed cases, we
noticed larger than expected 158-bp PCR products in three
patients (Fig. 1). These samples were subjected to sequence
analysis. Obtained sequence data were aligned to reference
fusion transcript sequences (SS18-SSX1—GenBank S79325,
SS18-SSX2—GenBank S79332) and analyzed using the
BLASTsoftware. Two patients carried novel SS18-SSX variant
translocations, and in one patient we detected atypical variant
that was previously described by Amary et al. in 2007 [13].
SS18-SSX1 variant described by Amary et al. (2007)
An unexpected PCR product of 194 bp was detected in SS of
patient #29. Direct sequencing indicated the identical SS18-SSX1








Fig. 3 Identification of novel fusion transcript SS18-SSX2. a Schema-
tic representation of the expected PCR product and novel SS18-SSX2
fusion transcript. In the upper part of the picture, the nucleotide
positions derived from the original sequences of SS18 and SSX2
mRNA are indicated. b Nucleotide sequence of the 263-bp PCR
product with predicted amino acid sequence of the chimeric protein
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coworkers [13]. This variant includes additional 12 codons de-
rived from exon 5 of SSX1, which results in the fusion of codon
410 of SS18 to codon 99 of SSX1 without reading frame shift.
Amary et al. described this transcript variant in a 24-year-old
male with a 30-mm tumor located in the right triceps. The tumor
was classified as monophasic with 50 % of necrosis and 19
mitotic figures per 10 high-power fields. Patient #29 in our study
was a 33-year-old male presenting biphasic a 30-mm tumor in
the right knee, with less than 50 % of necrosis and two mitotic
figures per 10 high-power fields. The patient underwent tumor
resection directly after first diagnosis, and he was alive without
disease 42 months after surgery.
Novel SS18-SSX1 variant
Tumor specimen #3 was obtained from an 85-year-old fe-
male with a tumor of 105-mm maximal diameter located in
the shoulder. Additionally, a 30-mm metastatic tumor spec-
imen from deep tissues of the shoulder was available from
the same patient (metastasis developed 11 months after
initial diagnosis). FISH analysis indicated SS18-SSX1 fusion
transcript in both of these specimens.
PCRwith primers specific for the SS18-SSX1 fusion transcript
presented larger than expected products in both of the specimens.
The nucleotide sequences of amplified products were identical.
BLAST analysis showed an insertion of 186 bp in the site of
usual SS18-SSX1 junction. The additional nucleotides corre-
sponded to 136 bp of complete exon 6 of RALBP1 associated
Eps domain containing 2 (REPS2) (NM_004726.2) and 50 bp of
complete exon 5 of SSX1, indicating a complex rearrangement in
this tumor (Fig. 2). REPS2-SSX1 insert was fused to the codon
410 of SS18 at the 5′ end and to the codon 111 of SSX1 at the 3′
end. This rearrangement maintained the original reading frame.
The predicted chimeric protein contains 410 N-terminal codons
of SS18, followed by 62 codons of REPS2-SSX1 fragment
(codon 46 for valine situated at the junction site of these two
genes) and 78 C-terminal codons of SSX1.
Novel SS18-SSX2 variant
We detected the third unusual fusion variant in a specimen
#16, derived from a 56-year-old male with a 80-mm mono-
phasic SS primary tumor located in the stomach. Patient
underwent tumor resection directly after diagnosis. He de-
veloped metastasis after 13 months and was alive with
disease after 42 months. FISH analysis indicated SS18-
SSX2 fusion transcript in this specimen. PCR with primers
specific for SS18-SSX2 amplified larger than expected prod-
uct of 263 bp. The insertion of additional 105 bp was fused
in the position of usual SS18-SSX2 junction point. Codon
410 of SS18 at the 5′ portion of fusion was followed by
29 bp of intron 10 of SS18, 14 bp of exon 5 of SSX2, 62 bp
of intron 5 of SSX2, and 91 bp of exon 6 of SSX2, which is
usually present in the 3′ end of the fusion transcript (Fig. 3).
This insertion conserved the original reading frame.
Discussion
The most common SS18-SSX fusion transcripts involve
410 N-terminal codons of SS18 and 78 C-terminal codons
Fig. 4 Schematic representation of novel fusion sites in the unusual
transcript variants of SS18-SSX1 (a), SS18-SSX2 (b), and SS18-SSX4
(c) described in the literature
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of either SSX1 or SSX2. To the best of our knowledge, there
are 17 reports describing atypical variants of SS-associated
translocations, which are mostly caused by small insertions
[4, 7, 11–14, 23–32]. Novel SS18-SSX transcript variants are
frequently created not only by the unusual junction of SS18
and one of SSX genes but also by the mutations within SS18
or SSX genes which occur apart from the fusion site, e.g.,
deletion or truncation of SSX1 [26, 32] or insertion in SS18
sequence [12]. Figure 4 presents previously reported fusion
variants characterized by different SS18-SSX junction sites.
Our examination of fusion transcript type in a series of 40
SS primary tumor specimens revealed three unusual tran-
script variants, two of which were not published before.
The first unusual SS18-SSX1 transcript variant detected in
our study was earlier described by Amary et al. [13]. Our
detection of the identical fusion transcript variant confirms
that the rare variants can be recurrent in SS patients and they
are probably not caused by unique nor random events.
Similar observations were already reported in several pub-
lications. Figure 4 indicates whether the atypical fusion
variant was described in more than a single case.
The novel SS18-SSX1 transcript variant was detected both
in primary and metastatic specimens derived from the same
patient. This translocation involved another gene, i.e., REPS2,
also known as POB1, located on the X chromosome at Xp22.
The product of this gene is involved in the growth factor
signaling and control of cell proliferation [33–36]. The ex-
pression of this gene might serve as a biomarker of favorable
outcome in breast and prostate cancers; conversely, REPS2
downregulation has been demonstrated in the progression of
prostate cancer [34, 37–39]. The fusion site of REPS2 and
SSX1 involves amino acids encoded across a splice junction—
codon 303 for glycine on the border of exons 6 and 7 of
REPS2 and codon 94 for valine at the junction of exons 4
and 5 of SSX1. Predicted chimeric protein sequence preserves
valine in this position. Noteworthy, the junction between
REPS2 and SSX1 was formed at the overlapping nucleotides
“GGT” which are present at the 3′ end portion of REPS2 and
5′ end portion of SSX1. Possibly, these overlapping nucleo-
tides created a preferential site for the fusion of these genes.
REPS2 exon 6, which is involved in this unusual fusion,
encodes a portion of the Eps15 homology domain (residues
282–373). This domain has been described to interact with
Epsin, Eps15, and p65 subunit of NFκB [37, 39]. However,
gene expression profiles of synovial sarcoma cases described
in the present study did not show any significant differences or
correlations concerning REPS2 and its interactors (unpub-
lished data). Therefore, the possible impact of REPS2 gene
involvement in SS-associated translocation remains unclear.
Apparently, this variant preserved the transforming function
of the usual SS18-SSX1 fusion oncogene, which indicates that
the mechanism of tumorigenesis in this case might have been
similar as in other synovial sarcoma cases.
In addition, we have also detected novel SS18-SSX2
fusion transcript variant that consists of exonic and intronic
regions of both SS18 and SSX2 genes. This transcript was
also presumably created by the alternative splicing mecha-
nism since there are two cryptic “AG” acceptor sites and one
cryptic “GT” donor site in the direct proximity of the fusion
points. First, there is an AG signal immediately before the
junction point of SS18 exon 10 and intron 10 in position
12615–12616 of original intron 10. Second, the cryptic
acceptor splice site is present immediately before the fusion
point of SS18 intron 10 and SSX2 exon 5, involving codons
104 and 105 of SSX2 exon 5. Finally, directly after the SSX2
intron 5 portion involved in the fusion, there is a cryptic
donor splice signal GT, which was presumably used with the
authentic acceptor splice site in the 3′ end of this intron,
resulting in the junction of SSX2 intron 5 and SSX2 exon 6.
Cryptic splicing mechanisms have previously been
reported in the unusual fusion transcript formation [28].
Our data confirm that alternative splicing may play an
important role in novel fusion transcript formation and that
it may be a recurrent event in SS.
In our series, 64 % of the patients carrying SS18-SSX1
translocation and 71 % of the patients with SS18-SSX2
fusion transcript developed local recurrence or metastasis.
This finding supports previous reports [9, 18, 19] showing
no significant correlation between fusion type and clinical
outcome.
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